NGM Bio to Participate in the B. Riley Securities 3rd Annual Oncology Conference
NGM Biopharmaceuticals, Inc. (NGM) will participate in the B. Riley Securities 3rd Annual Oncology Conference on January 19, 2023, at 11:00 am ET. CEO David J. Woodhouse, Ph.D., and CFO Siobhan Nolan Mangini will provide a business update focusing on NGM's oncology portfolio. A live webcast of the event will be available on NGM's website, and a replay will be accessible for 30 days post-event. NGM is dedicated to developing transformative therapeutics through biology-centric drug discovery, currently advancing five clinical programs.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and Siobhan Nolan Mangini, President and Chief Financial Officer, will participate in the B. Riley Securities 3rd Annual Oncology Conference and will provide a business update focusing on NGM Bio’s wholly-owned oncology portfolio on Thursday, January 19th, at 11:00 am ET.
A live webcast of the presentation will be available under the Investors and Media section of NGM Bio’s website at https://ir.ngmbio.com/events-presentations. A replay of the presentation will be archived on NGM Bio’s site for at least 30 days following the event.
About NGM Biopharmaceuticals, Inc.
NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, always led by biology and motivated by unmet patient need. Today, the company has five programs in active clinical development. Visit us at www.ngmbio.com for more information.
| Investor Contact: Brian Schoelkopf ir@ngmbio.com | Media Contact: media@ngmbio.com |
FAQ
When is NGM participating in the B. Riley Securities Oncology Conference?
Who will represent NGM at the Oncology Conference?
Where can I watch the NGM presentation from the Oncology Conference?
How long will the replay of NGM's presentation be available?
What is NGM's focus in drug development?
